Clinical Trial Update: A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for SHR-1210 plus Apatinib in soft tissue sarcoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Sarcoma | Phase 2 | Status: TERMINATED | Results posted: 2024-02-29